Mark Monane
YOU?
Author Swipe
View article: Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study
Implementation of an Alzheimer’s Disease Blood Test: Adoption Experience by Memory Care Specialists in a Multi-Center Study Open
Background/Objectives: A high-performing blood biomarker (BBM) test for Alzheimer’s disease (AD) represents an accurate, accessible, and scalable tool to aid healthcare professionals (HCPs) evaluating patients presenting with signs or symp…
View article: Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform
Plasma phospho-tau217 for Alzheimer’s disease diagnosis in primary and secondary care using a fully automated platform Open
Global implementation of blood tests for Alzheimer’s disease (AD) would be facilitated by easily scalable, cost-effective and accurate tests. In the present study, we evaluated plasma phospho-tau217 (p-tau217) using predefined biomarker cu…
View article: Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study
Clinical Utility of an Alzheimer’s Disease Blood Test Among Cognitively Impaired Patients: Results from the Quality Improvement PrecivityAD2 (QUIP II) Clinician Survey Study Open
Objective: The objective of this study was to assess clinical decision-making associated with the use of a multi-analyte blood biomarker (BBM) test among patients presenting with signs or symptoms of mild cognitive impairment or dementia. …
View article: EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT Open
There is an important unmet need for timely, noninvasive, low-burden diagnostic tools to aid in Alzheimer’s disease evaluation. The AAA-BBM2 (PrecivityAD2™) blood test combines plasma amyloid beta (AB)42/40 Ratio and phosphorylated-tau217/…
View article: Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care
Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care Open
Background An accurate blood test for Alzheimer’s disease (AD) could streamline the diagnostic work‐up and treatment of AD. Our aim was to evaluate an AD blood test in primary and secondary care, using predefined biomarker cutoffs and pros…
View article: EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT
EARLY CLINICAL UTILITY DATA OF A MULTI-ANALYTE BLOOD BIOMARKER TEST FOR EVALUATING COGNITIVE IMPAIRMENT Open
There is an important unmet need for timely, noninvasive, low-burden diagnostic tools to aid in Alzheimer’s disease evaluation. The AAA-BBM2 (PrecivityAD2™) blood test combines plasma amyloid beta (AB)42/40 Ratio and phosphorylated-tau217/…
View article: IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY
IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY Open
Recent studies have shown that commercially available, high-performing blood biomarkers (BBMs) for Alzheimer’s disease (AD) pathology represent accurate, accessible, acceptable, and equitable tools to aid health care providers (HCPs) in th…
View article: Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease
Considerations for widespread implementation of blood‐based biomarkers of Alzheimer's disease Open
Diagnosing Alzheimer's disease (AD) poses significant challenges to health care, often resulting in delayed or inadequate patient care. The clinical integration of blood‐based biomarkers (BBMs) for AD holds promise in enabling early detect…
View article: Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease
Recommendations for clinical implementation of blood‐based biomarkers for Alzheimer's disease Open
Blood‐based biomarkers (BBM) for Alzheimer's disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cereb…
View article: Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care
Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care Open
Importance An accurate blood test for Alzheimer disease (AD) could streamline the diagnostic workup and treatment of AD. Objective To prospectively evaluate a clinically available AD blood test in primary care and secondary care using pred…
View article: Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease Open
Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests …
View article: Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment
Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment Open
More than 16 million Americans living with cognitive impairment warrant a diagnostic evaluation to determine the cause of this disorder. The recent availability of disease-modifying therapies for Alzheimer's disease (AD) is expected to sig…
View article: Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid
Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid Open
BACKGROUND With the availability of disease‐modifying therapies for Alzheimer's disease (AD), it is important for clinicians to have tests to aid in AD diagnosis, especially when the presence of amyloid pathology is a criterion for receivi…
View article: A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care setting
A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care setting Open
Aims The aim of the study was to assess the real-world feasibility, acceptability, and impact of an integrated risk tool for cardiovascular disease (CVD IRT, combining the standard QRISK®2 risk algorithm with a polygenic risk score), imple…
View article: Detection of Early Alzheimer’s disease at AdventHealth: A Davos Alzheimer’s Collaborative flagship site
Detection of Early Alzheimer’s disease at AdventHealth: A Davos Alzheimer’s Collaborative flagship site Open
Background Early identification of Alzheimer’s disease (AD) is critical for disease‐modifying therapies. The Davos Alzheimer’s Collaborative flagship program tested the feasibility of implementing a digital cognitive assessment (DCA) follo…
View article: PATIENT AGE AND SEX DO NOT APPEAR TO INFLUENCE DECISION MAKING AROUND BIOMARKER TESTING FOR COGNITIVE IMPAIRMENT
PATIENT AGE AND SEX DO NOT APPEAR TO INFLUENCE DECISION MAKING AROUND BIOMARKER TESTING FOR COGNITIVE IMPAIRMENT Open
The QUIP I Study (ClinicalTrials.gov Identifier: NCT05477056) was a prospective, single-arm study which included 347 older persons (average age 74, 56% women) presenting with signs and symptoms of cognitive impairment. In a subgroup analys…
View article: A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment Open
Objective The objective of this study was to examine clinicians' patient selection and result interpretation of a clinically validated mass spectrometry test measuring amyloid beta and ApoE blood biomarkers combined with patient age (Preci…
View article: Early Clinical Utility Data of a Blood Biomarker Test in the Evaluation of Mild Cognitive Impairment
Early Clinical Utility Data of a Blood Biomarker Test in the Evaluation of Mild Cognitive Impairment Open
There is an important unmet need for timely, noninvasive, low-burden evaluation of patients presenting with mild cognitive impairment (MCI). The PrecivityAD™ blood test quantifies plasma concentrations of amyloid-β 42 and 40 and apolipopro…
View article: The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry
The Clinical Utility of a Precision Medicine Blood Test Incorporating Age, Sex, and Gene Expression for Evaluating Women with Stable Symptoms Suggestive of Obstructive Coronary Artery Disease: Analysis from the PRESET Registry Open
Background: Evaluating women with symptoms suggestive of coronary artery disease (CAD) remains challenging. A blood-based precision medicine test yielding an age/sex/gene expression score (ASGES) has shown clinical validity i…
View article: Utility of a Precision Medicine Test in Elderly Adults with Symptoms Suggestive of Coronary Artery Disease
Utility of a Precision Medicine Test in Elderly Adults with Symptoms Suggestive of Coronary Artery Disease Open
Background Diagnosing obstructive coronary artery disease ( CAD ) is challenging in elderly adults, and current diagnostic approaches for CAD expose these individuals to risks from contrast dye and invasive procedures. Design A Registry to…
View article: Clinical Utility of a Precision Medicine Test Evaluating Outpatients with Suspected Obstructive Coronary Artery Disease
Clinical Utility of a Precision Medicine Test Evaluating Outpatients with Suspected Obstructive Coronary Artery Disease Open
In this community-based cardiovascular registry, the ASGES demonstrated clinical utility in the evaluation of patients with suspected obstructive coronary artery disease. Low-score patients were less likely to undergo cardiac referral, wer…
View article: An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial
An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial Open
A blood-based genomic test for detecting oCAD significantly predicts near-term revascularization procedures, but not non-revascularization events. Larger studies will be needed to clarify the risk with non-revascularization events.
View article: The Diagnosis of CAD in Women: Addressing the Unmet Need—A Report from the National Expert Roundtable Meeting
The Diagnosis of CAD in Women: Addressing the Unmet Need—A Report from the National Expert Roundtable Meeting Open
A multistakeholder panel comprising experts in the fields of clinical cardiology, medical technology innovation, women's health research and policy analysis, personalized medicine, payers (including self-insured employers), patient advocac…